{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"920"},{"groupId":"OG001","value":"676"},{"groupId":"OG002","value":"459"},{"groupId":"OG003","value":"240"},{"groupId":"OG004","value":"187"}]}],"title":"Adverse Event Related to Drug"},{"categories":[{"measurements":[{"groupId":"OG000","value":"425"},{"groupId":"OG001","value":"333"},{"groupId":"OG002","value":"248"},{"groupId":"OG003","value":"110"},{"groupId":"OG004","value":"81"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"274"},{"groupId":"OG002","value":"205"},{"groupId":"OG003","value":"99"},{"groupId":"OG004","value":"62"}]}],"title":"Planned Change"},{"categories":[{"measurements":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"243"},{"groupId":"OG002","value":"179"},{"groupId":"OG003","value":"91"},{"groupId":"OG004","value":"62"}]}],"title":"Adverse Event Not Related to MM Therapy Drug"},{"categories":[{"measurements":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"107"},{"groupId":"OG002","value":"105"},{"groupId":"OG003","value":"47"},{"groupId":"OG004","value":"30"}]}],"title":"Current Dose Tolerated, Dose Increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"91"},{"groupId":"OG002","value":"65"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"22"}]}],"title":"Dose Delay Due to Toxicity"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"39"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"16"}]}],"title":"Patient/Family Preference"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"13"}]}],"title":"Treatment Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"13"}]}],"title":"Lack of Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"8"}]}],"title":"COVID-19 Restrictions"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"7"}]}],"title":"Relapse - Biochemical Progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"3"}]}],"title":"COVID-19 Diagnosis (Confirmed Positive)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"}]}],"title":"Relapse - Symptomatic/Clinical Progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"title":"COVID-19 Diagnosis (Suspected Positive)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"}]}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2260"},{"groupId":"OG001","value":"1878"},{"groupId":"OG002","value":"1416"},{"groupId":"OG003","value":"700"},{"groupId":"OG004","value":"500"}],"units":"Participants"}],"groups":[{"description":"The most common treatment regimens prescribed in participants treated in 1st line of therapy were PI+IMiD, PI+AA, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG000","title":"1st Line of Therapy"},{"description":"The most common treatment regimens prescribed in participants treated in 2nd line of therapy were PI+IMiD, IMiD, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG001","title":"2nd Line of Therapy"},{"description":"The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG002","title":"3rd Line of Therapy"},{"description":"The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG003","title":"4th Line of Therapy"},{"description":"The most common treatment regimens prescribed in participants treated in \\>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG004","title":">4th Line of Therapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Enrolled Population included all participants who signed informed consent. Participants received more than one LOT and are counted in more than one LOT. The data is reported as per the known line of therapies. Participants were counted multiple times in different categories. The overall number of participants analyzed is the number of participants available for analyses.","reportingStatus":"POSTED","timeFrame":"Baseline up to 5 years","title":"Reasons for Treatment Modifications","type":"SECONDARY","unitOfMeasure":"Participants"}